Discover
OVID
Ovid Therapeutics Inc.
2.63
1 x 2.14
1 x 2.74
bid
ask
-
0.02
0.75%
1 @ 04:00 PM
2.68 +0.05 (1.90%)
| Ytd | 61.35% | |
| 1y | 414.68% |
2.60
day range
2.63
0.51
52 week range
2.96
| Open | 2.63 | Prev Close | 2.65 | Low | 2.60 | High | 2.63 | Mkt Cap | 490.86M |
| Vol | 914.88K | Avg Vol | 2.41M | EPS | -0.29 | P/E | -9.07 | Forward P/E | -2.44 |
| Beta | 0.41 | Short Ratio | 3.05 | Inst. Own | 56.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 2.45 | 200-d Avg | 2.04 | 1yr Est | 3.26 |
OVID News
zacks.com
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a like
benzinga.com
Ovid Therapeutics Promotes Charles Carter As CFO Succeeding Jeffrey Rona
Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions,